Wall Street analysts have issued a 77.68% upside price target on Evolus (NASDAQ: EOLS), signaling confidence in the company's near-term trajectory. The projection reflects optimism around Evolus's execution on Dysport market share gains and international expansion of its proprietary neuromodulator Estyme, which has now launched in Canada, Australia, and New Zealand.
Business & M&A
Wall Street Sees 77% Upside in Evolus Stock
Analysts project significant gains for the Dysport and Estyme maker amid market momentum.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Analysts project 77.68% upside on Evolus stock amid Dysport gains.
The stock move follows Evolus's second consecutive quarter of earnings beats and guidance raises. For practice owners, the signal matters: a strengthening Evolus balance sheet and stock price typically translate to more aggressive rebate programs, expanded loyalty incentives through Evolus Rewards, and competitive pricing pressure on AbbVie's Botox and Galderma's Xeomin. Watch for promotional intensity to spike if the stock sustains momentum.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.